Drug Information Related to Lenalidomide
Back
01. Data Presented at ASCO Finds REVLIMID as a Monotherapy is Effective an...
Study Further Validates REVLIMID's Role in the Treatment of Multiple Myeloma Helping to Change the Previously Incurable Blood Cancer into a Chronic, Manageable Disease
...
02. Cancer Researchers at Manhattan-based St. Vincent's Comprehensive ......
Study Points to the Increasing Use of Genetic Testing to Measure the Clinical Benefits of Pharmaceuticals
...
03. Clinical Data For REVLIMID® And VIDAZA® In Important Blood Cancers ....
BOUDRY, Switzerland -- Celgene International Sarl (Nasdaq: CELG):
...
04. Preliminary Results from International Study Report That REVLIMID ......
COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG) today announced that preliminary data from an international study of single agent REVLIMID (lenalidomide) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) were presented at the 13th Congress...
05. New Analysis of Phase III Studies Shows That REVLIMID® Plus ...
Longer Survival Than Previously Demonstrated
...
06. Health Economic Analysis Reports That Revlimid is a Cost Effective ......
COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID ...
07. Schools of Pharmacology | Journal of Drugs in Dermatology | Find ......
Schools in Pharmacology is a new feature that will appear periodically. It will explicate the dermatologic uses and side effects of new medications and devices. It follows medications mentioned in the Pipeline Previews into their approval and use in clinical practice....
08. Multiple Clinical Trials of VELCADE® for Injection Based Therapies .....
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with ...
09. Oral Cancer Drug REVLIMID® Receives Swissmedic Approval in Switzerlan...
SUMMIT, N.J. -- Celgene International Sarl (NASDAQ: CELG) announced today that it's oral cancer drug, REVLIMID (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment f...
10. Updated REVLIMID® Plus Dexamethasone Data in Previously Treated ......
Major Phase III Studies Report Oral REVLIMID Plus Dexamethasone Shows Time to Disease Progression and Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma
...
11. Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with ....
-- Trial Initiation Triggers $4 Million Milestone Payment from
Genentech --
BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced
today that it has initiated a phase Ib clinical trial of SGN-40 in
combination with Revlimid[R] (lenalidomide) and dexa...
12. REVLIMID(R) Data for Newly Diagnosed Multiple Myeloma Reported at a .....
COPENHAGEN, Denmark -- Data from the ECOG E4A03 and SWOG 0232
studies were reported at a Satellite Symposium and showed that newly
diagnosed multiple myeloma patients who are eligible for a transplant,
obtain better outcomes when treated with REVLIMID (lenalidomi...
13. Preliminary Results from International Study Report That REVLIMID(R .....
COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG)
today announced that preliminary data from an international study of
single agent REVLIMID (lenalidomide) in relapsed/refractory aggressive
non-Hodgkin's lymphoma (NHL) were presented at the 13th Con...
14. ImmunoGen, Inc. Announces Presentations at the American Association fo...
WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops targeted anticancer therapeutics
using its Tumor-Activated Prodrug (TAP) technology, today announced that
the following will be reported at the Annual Meeting of the Ameri...
15. SEATTLE GENETICS HAS FIRST QTR 2008 NET LOSS OF $17.I MIL. - Free ......
Seattle Genetics, Inc. (Nasdaq:SGEN) Bothell, Wash., has reported
financial results for the first quarter of 2008. "We continue to
advance and expand our robust product pipeline, including recent trial
initiations with each of our clinical programs, SGN-40, SGN-3...
16. 113 Abstracts Evaluating Celgene Products to Be Presented at the 49th ...
Sixty-five Abstracts Investigating REVLIMID([R]) in a Broad Range
of Hematological Cancers
SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) announced today
that clinical investigators from leading cancer research centers will
present data from recent and on-...
17. SEATTLE GENETICS HAS FIRST QTR 2008 NET LOSS OF $17.I MIL. - Free ......
Seattle Genetics, Inc. (Nasdaq:SGEN) Bothell, Wash., has reported
financial results for the first quarter of 2008. "We continue to
advance and expand our robust product pipeline, including recent trial
initiations with each of our clinical programs, SGN-40, SGN-3...
18. 113 Abstracts Evaluating Celgene Products to Be Presented at the 49th ...
Sixty-five Abstracts Investigating REVLIMID([R]) in a Broad Range
of Hematological Cancers
SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) announced today
that clinical investigators from leading cancer research centers will
present data from recent and on-...
19. New Analysis of Phase III Studies Shows That REVLIMID(R) Plus ...
Longer Survival Than Previously Demonstrated
COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG)
today announced that according to data from a pooled study presented at
the 13th European Hematology Association (EHA) congress in Copenhagen,
Denmark,...
20. Health Economic Analysis Reports That Revlimid is a Cost Effective ......
COPENHAGEN, Denmark -- Celgene International Sarl (Nasdaq:CELG)
announced that data presented today at the 13th Congress of the European
Hematology Association (EHA) in Copenhagen, Denmark found that patients
previously treated for multiple myeloma receiving REVL...
21. Celgene CEO Dr. Sol J. Barer to Appear Live on ''Corporate Strategies ...
HOUSTON -- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: CELGENE CEO DR. SOL J. BARER TO APPEAR LIVE ON "CORPORATE STRATEGIES WITH TIM CONNOLLY" SUNDAY, JULY 2, 2006 AT 9:00 P.M. EST Dr. Bar...
